NASDAQ:REPL - Replimune Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.21
  • Forecasted Upside: -2.18 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$45.20
▲ +1.81 (4.17%)
1 month | 3 months | 12 months
Get New Replimune Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$44.21
▼ -2.18% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $44.21, with a high forecast of $54.00 and a low forecast of $12.50. The average price target represents a -2.18% upside from the last price of $45.20.
Buy
The current consensus among 7 polled investment analysts is to buy stock in Replimune Group.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$40.00 ➝ $51.00High
i
10/15/2020BarclaysBoost Price TargetOverweight$29.00 ➝ $50.00High
i
Rating by Peter Lawson at Barclays PLC
10/15/2020HC WainwrightUpgradeNeutral ➝ Buy$25.00 ➝ $54.00High
i
Rating by R. Burns at HC Wainwright
10/15/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $44.00High
i
10/14/2020Roth CapitalBoost Price TargetBuy$30.00 ➝ $50.00High
i
10/14/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $48.00High
i
Rating by Geulah Livshits at Chardan Capital
8/7/2020Chardan CapitalReiterated RatingBuy$30.00High
i
Rating by Geulah Livshits at Chardan Capital
8/7/2020SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $27.00Low
i
7/1/2020HC WainwrightReiterated RatingBuy ➝ Neutral$25.00High
i
Rating by Robert Burns at HC Wainwright
6/4/2020BMO Capital MarketsBoost Price TargetOutperform$31.00 ➝ $40.00High
i
6/4/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $25.00High
i
Rating by R. Burns at HC Wainwright
6/4/2020BarclaysBoost Price TargetOverweight$21.00 ➝ $25.00High
i
Rating by Peter Lawson at Barclays PLC
6/4/2020Chardan CapitalReiterated RatingBuy$29.00High
i
Rating by Geulah Livshits at Chardan Capital
6/3/2020WedbushReiterated RatingOutperformMedium
i
Rating by R. Driscoll at Wedbush
5/4/2020BarclaysInitiated CoverageOverweight$21.00High
i
Rating by Peter Lawson at Barclays PLC
2/13/2020Chardan CapitalReiterated RatingBuy$28.00Low
i
Rating by Geulah Livshits at Chardan Capital
1/21/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $24.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/20/2019WedbushLower Price TargetOutperform$30.00 ➝ $12.50Medium
i
11/11/2019Roth CapitalBoost Price TargetBuy$20.00 ➝ $30.00Low
i
Rating by T. Butler at Roth Capital
10/24/2019Chardan CapitalReiterated RatingBuy$28.00Low
i
Rating by Geulah Livshits at Chardan Capital
10/15/2019Chardan CapitalSet Price TargetBuy$28.00High
i
Rating by Geulah Livshits at Chardan Capital
9/30/2019HC WainwrightReiterated RatingBuy$26.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/4/2019Roth CapitalInitiated CoverageBuy$20.00High
i
Rating by T. Butler at Roth Capital
8/15/2019Chardan CapitalReiterated RatingBuy$28.00Medium
i
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$28.00Low
i
7/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$27.00 ➝ $26.00Low
i
7/8/2019HC WainwrightInitiated CoverageBuy ➝ Buy$26.00Low
i
Rating by R. Selvaraju at HC Wainwright
4/24/2019WedbushInitiated CoverageOutperform ➝ Outperform$24.00High
i
Rating by R. Driscoll at Wedbush
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
i
8/14/2018SVB LeerinkInitiated CoverageOutperform$25.00Low
i
Rating by J. Chang at SVB Leerink LLC
8/14/2018BMO Capital MarketsInitiated CoverageOutperform$31.00Low
i
8/14/2018JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Low
i
(Data available from 10/26/2015 forward)
Replimune Group logo
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $45.20
$43.21
$46.19

50 Day Range

MA: $26.81
$20.64
$43.39

52 Week Range

Now: $45.20
$8.58
$47.96

Volume

1,401,300 shs

Average Volume

278,821 shs

Market Capitalization

$1.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.23